TECHWIRE 30
(CIX: WRAL30)  1,100.59  up arrow+8.66  (0.79 %)  Updated: 08:10 PM EDT, Aug 19 2014
(NQ: Apple)  100.53  up arrow+1.37  (1.38 %)  Updated: 08:10 PM EDT, Aug 19 2014
(NY: QUINTILES)  56.13  down arrow-0.95  (-1.66 %)  Updated: 06:40 PM EDT, Aug 19 2014
(OP: BASF SE)  102.13  up arrow+0.11  (0.11 %)  Updated: 08:10 PM EDT, Aug 19 2014
(NQ: BioCryst)  13.40  down arrow-0.5  (-3.6 %)  Updated: 08:10 PM EDT, Aug 19 2014
(NQ: BioDelivery)  14.01  up arrow+0.62  (4.63 %)  Updated: 08:10 PM EDT, Aug 19 2014
(NQ: CEMP)  9.72  up arrow+0.09  (0.93 %)  Updated: 08:10 PM EDT, Aug 19 2014
(NQ: Cisco Systems)  24.64  up arrow+0.01  (0.04 %)  Updated: 08:10 PM EDT, Aug 19 2014
(NQ: Cree)  45.53  up arrow+0.61  (1.35 %)  Updated: 08:10 PM EDT, Aug 19 2014
(NQ: DARA)  1.28  up arrow+0.01  (0.79 %)  Updated: 08:10 PM EDT, Aug 19 2014
(NY: EMC CORPORATION)  29.89  down arrow-0.06  (-0.2 %)  Updated: 06:40 PM EDT, Aug 19 2014
(NQ: Extreme Networks)  5.24  up arrow+0.03  (0.58 %)  Updated: 08:10 PM EDT, Aug 19 2014
(NQ: FB)  75.29  up arrow+0.7  (0.94 %)  Updated: 08:10 PM EDT, Aug 19 2014
(NY: GLAXOSMITHKLINE)  47.35  down arrow-0.11  (-0.23 %)  Updated: 06:40 PM EDT, Aug 19 2014
(NQ: GOOG)  586.86  up arrow+4.7  (0.81 %)  Updated: 08:10 PM EDT, Aug 19 2014
(NY: IBM)  190.07  up arrow+0.71  (0.38 %)  Updated: 06:40 PM EDT, Aug 19 2014
(NY: LH)  105.80  up arrow+0.45  (0.43 %)  Updated: 06:40 PM EDT, Aug 19 2014
(OP: Lenovo Group)  31.26  up arrow+0.84  (2.76 %)  Updated: 08:10 PM EDT, Aug 19 2014
(NY: MRK)  58.91  up arrow+0.49  (0.84 %)  Updated: 06:40 PM EDT, Aug 19 2014
(NQ: Microsoft Corp)  45.33  up arrow+0.22  (0.49 %)  Updated: 08:10 PM EDT, Aug 19 2014
(NQ: NTAP)  40.83  down arrow-0.28  (-0.68 %)  Updated: 08:10 PM EDT, Aug 19 2014
(NY: NOVARTIS AG)  88.63  up arrow+1.13  (1.29 %)  Updated: 06:40 PM EDT, Aug 19 2014
(OP: Novozymes A/S)  46.60  up arrow+0.86  (1.88 %)  Updated: 08:10 PM EDT, Aug 19 2014
(NY: PFIZER)  28.94  up arrow+0.1  (0.35 %)  Updated: 06:40 PM EDT, Aug 19 2014
(NQ: Pozen)  7.86  down arrow-0.04  (-0.51 %)  Updated: 08:10 PM EDT, Aug 19 2014
(NY: RED HAT)  62.54  up arrow+1.57  (2.58 %)  Updated: 06:40 PM EDT, Aug 19 2014
(NQ: BBRY)  9.85  up arrow+0.1  (0.97 %)  Updated: 08:10 PM EDT, Aug 19 2014
(NQ: Salix)  160.80  up arrow+21.63  (15.54 %)  Updated: 08:10 PM EDT, Aug 19 2014
(NQ: SQI)  15.15  up arrow+0.06  (0.4 %)  Updated: 08:10 PM EDT, Aug 19 2014

Posts tagged “BDSI”

June 9

Premium Lock BioDelivery Sciences could soar with FDA approval of Bunavail

More than two million people suffer from opioid dependence in the United States. BioDelivery's FDA approval for Bunavail may open up tremendous revenue streams for the Raleigh-based drug company.

How BDSI technology works How BDSI technology works

March 27

Premium Lock BioDelivery Sciences picks Quintiles to help launch proposed drug

Raleigh-based BioDelivery Sciences recently raised $60 million to help commercialize its proposed chronic pain reliever drug and hopes to win FDA approval for it in June. On Thursday, BDSI said it had chosen Durham-based Quintiles, the world's largest life science services firm, to help take the drug to market. The deal includes formation of a sales force.

How BDSI technology works How BDSI technology works

Updated February 10

Premium Lock Pain drug firm BioDelivery Sciences raising $60M in stock sale

BDSI Capitalizing on news that its chronic pain drug BEMA buprenorphine showed positive top-line phase III clinical trial results, BioDelivery Sciences International is raising $60 million to finance commercialization efforts.

January 24

Premium Lock Pain drug from BDSI shows positive trial results, triggers $10M milestone

BDSI Chronic pain drug BEMA buprenorphine showed positive top-line phase III clinical trial results, and securing trial data for further analysis has triggered a $10 million milestone to BioDelivery Sciences International.

December 3, 2013

Premium Lock BDSI hires key sales executive ahead of expected 2014 drug launch

BDSI's drug pipeline BioDelivery Sciences International's opioid dependence treatment Bunavail faces an FDA decision date of June 7 and the Raleigh company is getting ready to go to market if it secures regulatory approval.

Updated December 2, 2013

Premium Lock BioDelivery Sciences targets more tests for neuropathy treatment after 'positive' FDA meeting

Diabetes BioDelivery Sciences invested a mix of stock and cash that could total nearly $40 million if a proposed gel to treat diabetic neuropathy pain wins FDA approval, and the company says it will proceed with further tests after a "positive" meeting with regulators.

Updated October 21, 2013

Premium Lock BioDelivery Sciences names new chief financial officer

BDSI The Raleigh-based firm says its current CFO Jim McNulty will assume a new role as senior vice president for finance and treasurer.

October 9, 2013

Premium Lock BioDelivery Sciences' opioid treatment could win FDA approval in '14

The Raleigh-based drug delivery technology firm projects sales of up to $250 million if the opioid dependence treatment wins FDA approval next year.

How BDSI technology works How BDSI technology works

August 15, 2013

Premium Lock BDSI makes drug pipeline progress but reports $13.1M 2Q loss

BDSI BDSI swings to a $13.1 million loss in the second quarter, a change that reflects the $15 million milestone payment the company recorded in the second quarter of 2012.

August 1, 2013

Premium Lock Opioid dependence treatment from BDSI filed for FDA approval

BDSI's drug pipeline With Bunavail, BDSI aims to secure FDA approval on the first opioid dependence treatment that delivers abuse deterrents through the lining of the cheek.

July 29, 2013

Premium Lock BioDelivery Sciences' pain killer wins OK in Taiwan

BDSI The approval triggers a $300,000 milestone payment and future royalties from BDSI's partner in the island nation.

July 12, 2013

Premium Lock Drug delivery and more: BDSI flashes potential of revived drug pipeline

BioDelivery Sciences International's current pipeline reflects a shift in direction and a effort to stretch beyond the drug-delivery technology that was the initial focus for the company. Learn more about BDSI's strategy.

BDSI's drug pipeline BDSI's drug pipeline

July 8, 2013

Premium Lock BDSI lands $20M loan to support drug application, clinical trials

BDSI The $20 million loan shores up BDSI's finances as it prepares a new drug application for Bunavail and finishes phase III trials on a chronic pain drug candidate.

Updated March 26, 2013

Premium Lock Raleigh drug firm BDSI pays up to $40M for pain drug candidate

BDSI BioDelivery Sciences strikes a deal to license a potential treatment for diabetic neuropathy with privately held Arcion Therapeutics. The mix of stock and cash could total nearly $40 million if the drug wins approval.

January 22, 2013

Premium Lock Raleigh drug firm BDSI reports positive results of opioid dependence treatment

BDSI BioDelivery Sciences International says its proposed alternative treatment for opioid-dependent patients is safe and is safely tolerated when users of another product are switched.

November 29, 2012

Premium Lock Raleigh-based BDSI raises $40M in stock sale

Institutional investors have agreed to buy nearly 6.8 million of BDSI common shares and 2.7 million of newley designated Series A convertible preferred stock for an aggregate price of $4.21 each.

BDSI's product pipeline BDSI's product pipeline

September 14, 2012

Premium Lock SciQuest grants; Lenovo film winners; Quintiles deal; BDSI good news; Gentris expands

Bulldog Inside the Bulldog Blog: SciQuest picks five charitable grant winners; Lenovo names winners in film contest; Quintiles lands deal in Mexico; BDSI reports good news on drug; Gentris expands headquarters.

August 20, 2012

Premium Lock In the news: AT&T, FaceTime plan, IBM, Epic investor, BDSI

Bulldog Inside the Bulldog Blog: AT&T may stop discounted table sales; groups protest AT&T FaceTime plan; IBM loses top outsourcer; investor in Epic Games eyes more growth; BDSI completes trial enrollment.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Dr. Mike Walden
Tech economy
Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Scroll